异动解读|ImmunityBio, Inc.盘中上涨4.31%,Anktiva海外推进与临床进展继续支撑情绪

行情直击
Nov 18

11月18日,ImmunityBio, Inc.盘中上涨4.31%,报6.53美元/股,成交额1246.63万美元。

消息面上,市场继续交易Anktiva近期在海外商业化和临床推进上的积极进展,带动公司产品落地预期回升。

近期公司披露,Anktiva已获以色列卫生部批准用于特定膀胱癌治疗,注册许可预计数周内发放;欧洲方面已有首批患者接受治疗;同时其膀胱癌注册性试验达到主要终点。尽管公司第三季度营收4884.1万美元、低于预期的5925万美元,且每股净亏损扩大至0.18美元,但产品端进展仍对股价形成支撑。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10